193 related articles for article (PubMed ID: 17292735)
1. Introduction: chronic myelogenous leukemia (CML).
Jabbour E; Kantarjian H
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
[No Abstract] [Full Text] [Related]
2. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
3. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
4. Treating cancer's kinase 'addiction'.
Baselga J; Arribas J
Nat Med; 2004 Aug; 10(8):786-7. PubMed ID: 15286778
[No Abstract] [Full Text] [Related]
5. New-age drug meets resistance.
McCormick F
Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
[No Abstract] [Full Text] [Related]
6. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
[No Abstract] [Full Text] [Related]
7. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
8. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
9. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
10. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
11. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
12. Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
Tsapas A; Vlachaki E; Sarigianni M; Klonizakis F; Paletas K
Leuk Res; 2008 Apr; 32(4):674-5. PubMed ID: 17920117
[No Abstract] [Full Text] [Related]
13. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
14. [Imatinib--en epoch-making new drug against chronic myeloid leukemia].
Lakartidningen; 2003 Jun; 100(26-27):2283. PubMed ID: 12872372
[No Abstract] [Full Text] [Related]
15. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
16. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
17. [Chronic myeloid leukemia].
Hochhaus A
Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
[No Abstract] [Full Text] [Related]
18. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
19. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
20. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Shah NP; Sawyers CL
Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
[No Abstract] [Full Text] [Related]
[Next] [New Search]
